Cadila Pharmaceuticals, one of India’s leading research-driven pharmaceutical companies, has launched Dlorfast-M-Tablets, a new fixed-dose combination therapy containing Desloratadine (5 mg) and Montelukast (10 mg). The product is designed for the management of allergic rhinitis and urticaria and marks an important advance in addressing the growing burden of allergic disorders in India.
Allergic rhinitis and urticaria are chronic conditions that affect millions of people worldwide, causing recurrent sneezing, nasal congestion, itching, hives, and swelling. These conditions can significantly reduce productivity, impair sleep quality, and diminish overall well-being. In India, allergy-related health problems have increased steadily over the past decade, driven by factors such as rising pollution levels, changing lifestyles, and genetic predisposition.
Recognising this challenge, Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response, namely histamine and leukotriene, to provide broader and more effective symptom relief.
Desloratadine is a potent and selective histamine H₁-receptor antagonist that blocks histamine, the primary mediator responsible for itching, swelling, and other allergy symptoms. Montelukast is a highly selective leukotriene receptor antagonist that binds with high affinity to cysteinyl leukotriene receptors, preventing airway oedema, smooth muscle contraction, and other inflammatory reactions. Together, the combination works synergistically to deliver comprehensive relief that is superior to either antihistamines or leukotriene inhibitors alone.
Clinical evaluations have shown that the Desloratadine and Montelukast combination significantly improves respiratory allergic pathology symptoms. The once-daily dosage enhances patient compliance and tolerability, making it suitable for long-term management of allergies. Dlorfast-M – Tablet is indicated for adults and adolescents with allergic rhinitis and urticaria. It is administered orally once daily as a single tablet.
Commenting on the launch, Dr. Rajiv I. Modi, Chairman and Managing Director of Cadila Pharmaceuticals Limited, said: “With the launch of Dlorfast-M, Cadila Pharmaceuticals continues its mission to provide accessible, effective, and innovative therapies to patients. This dual-action formulation addresses both histamine and leukotriene pathways, offering superior symptom control and improving quality of life for people living with allergies.”
Cadila Pharmaceuticals has a strong track record in respiratory and allergy care. The introduction of Dlorfast-M strengthens the company’s portfolio in this therapeutic area and underscores its commitment to delivering world-class, affordable healthcare solutions for patients across India and beyond.